| Literature DB >> 15608976 |
Jerson Laks1, Marlos Rocha, Claudia Capitão, Romeu Côrtes Domingues, Giovanna Ladeia, Maurício Lima, Eliasz Engelhardt.
Abstract
Previous reports on the use of olanzapine in Huntington's disease (HD) used doses ranging from 10-30 mg. We report a case of HD with marked delusions and behavioral impairment assessed by the Unified Huntington's Disease Rating Scale at baseline and four months later treated with a low dose of olanzapine. The patient improved in motor, psychiatric and activity of daily living symptoms after four months of treatment. The response to a low dose of olanzapine in HD may be an indicator of efficacy in similar cases. Further randomized controlled trials can properly assess these findings.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15608976 DOI： 10.1590/s0004-282x2004000600030
Source DB: PubMed Journal: Arq Neuropsiquiatr ISSN： 0004-282X Impact factor: 1.420